HK Stock Market Move | HUTCHMED (00013) rose by more than 5%. Last year, the net profit increased 11 times year-on-year to $457 million.

HUTCHMED (00013) rose by more than 5%, reaching a 5.13% increase at the time of writing, trading at 22.14 Hong Kong dollars with a turnover of 2144.4 million Hong Kong dollars. On the news front, HUTCHMED released its full-year 2025 performance, with a total revenue of 549 million US dollars, a decrease of 12.96% year-on-year; and a net profit attributable to shareholders of 457 million US dollars, an increase of 1111.03% year-on-year. HUTCHMED provided full-year guidance for the consolidated revenue of its oncology/immunology business in 2026, ranging between 330 million and 450 million US dollars. This guidance reflects the continued growth momentum of HUTCHMED's commercial operations in China, the ongoing global commercial expansion of FRUZAQLA, and new collaboration opportunities for innovative candidate drugs.